Atogepant (MK-8031; MK8031; Qulipta), a gepant, is a novel, oral and potent calcitonin gene-related peptide receptor antagonist approved in September 2021 for medical use in the United States to prevent episodic migraines.

纯度：≥98%

CAS：1374248-81-3